Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.67
-0.50 (-3.80%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
July 14, 2023
Via
Benzinga
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories
July 12, 2023
Wall Street Journal
Via
Benzinga
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
July 12, 2023
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily
Via
Benzinga
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
June 21, 2023
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients...
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
3 AI Stocks That Could Skyrocket Your Wealth
June 20, 2023
AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point.
Via
InvestorPlace
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
June 13, 2023
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy...
Via
Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
June 08, 2023
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist.
Via
InvestorPlace
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
May 19, 2023
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to
Via
Benzinga
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
May 11, 2023
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...
Via
Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
May 11, 2023
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its
Via
Benzinga
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More
April 25, 2023
Equilibria Strengthens Women's Wellness With New CSO
Via
Benzinga
Earnings Scheduled For May 11, 2023
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
This Supercharged Dividend King Stock Might Soon Run Out of Steam
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 11, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!
Via
InvestorPlace
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
April 10, 2023
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday
Via
Investor's Business Daily
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
April 05, 2023
Millions of people are scrambling to get their ADHD medication. Here's why.
Via
Investor's Business Daily
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
April 04, 2023
B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...
Via
Benzinga
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
March 27, 2023
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.
Via
Investor's Business Daily
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
March 25, 2023
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...
Via
Talk Markets
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
March 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
March 16, 2023
Via
Benzinga
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
March 15, 2023
Via
Benzinga
Should You Give Up on Novavax?
March 03, 2023
After a spectacular 2020 performance, Novavax's shares have plummeted.
Via
The Motley Fool
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
March 02, 2023
The FDA made a bold move in the CRISPR gene-editing realm.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.